CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies.

Jan/2022

CancerAppy closed 2021 with €690K total raised.

Together with our collaborators, we have found a new therapeutic target for TNBCs that we are currently patenting.

l

Nov/2021

The Ministry of Science and Technology has granted Torres Quevedo research grant for our researcher Elisa Poyatos.

Sep/2021

CancerAppy raised a pre-seed round of € 50K

Sep/2021

Enisa has granted us a loan of 100K

CancerAppy has been selected to participate in the Spanish delegation of the 4YFN 2021 event

We released GeneReport 1.0

Dic/2020

Cancerappy obtained the positive resolution of the Neotec 2020 program.

l

Oct/2020

CancerAppy was one of the 24 projects selected to exhibit at the B-venture 2020 Bilbao.

Sep/2020

Version 6.0 AI 1.0

AI + Drug Interaction / Personalized Medicine

Apr/2020

Version 5.0

Code rewritten. Drug Interaction

Apr/2020

CancerAppy raised a pre-seed round of € 120K

Dec/2019

Version 4.0

Tested at 6 hospitals and universities

l

Aug/2019

Cancerappy is founded in Bilbao as a startup